Advacan

Everolimus is a semisynthetic derivative of the macrolide antibiotic sirolimus (rapamycin) that acts as a selective inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase central to cell growth and proliferation pathways.[1][2] By binding intracellularly to FKBP-12 and forming a complex that allosterically inhibits mTOR complex 1 (mTORC1), everolimus suppresses downstream signaling events including protein synthesis, angiogenesis, and glycolytic metabolism, thereby exerting immunosuppressive and antiproliferative effects.[1][2][3] Approved by the U.S. Food and Drug Administration under brand names such as Zortress for prophylaxis of organ rejection in kidney and liver transplantation and Afinitor for oncologic indications, it is indicated for advanced renal cell carcinoma refractory to prior therapies, hormone receptor-positive HER2-negative breast cancer in combination with exemestane, progressive neuroendocrine tumors of pancreatic origin, and subependymal giant cell astrocytoma in patients with tuberous sclerosis complex.[4][5][6] While effective in extending progression-free survival in these settings, everolimus is associated with notable toxicities including stomatitis, fatigue, diarrhea, and serious risks such as non-infectious pneumonitis, infections due to immunosuppression, and hyperglycemia, necessitating careful monitoring of trough levels and dose adjustments.[4][5][7]